Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML

By sjmartinez • June 29, 2023

Pratz KW, Cherry M, Altman JK, Cooper BW, Podoltsev NA, Cruz JC, Lin TL, Schiller GJ, Jurcic JG, Asch A, Wu R, Hill JE, Gill SC, James AJ, Rich ES, Hasabou N, Perl AE, Levis MJ. Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. J Clin Oncol. 2023 Jun 28:JCO2202721. doi: 10.1200/JCO.22.02721. Epub ahead of print. PMID: 37379495.

Tags: Hematology/Oncology, Publications

cfDNA derived gene signatures as surrogate for microvascular invasion in HCC

Gong R, Wang L, Xue D, Cai J, Jiang Y, Huang J, Zhu J, Li Z, Ke A, Shi G, Wang J, Wang W, Zheng[...]

Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT)

Skoulidis F, Jabbour SK, Garon EB, Iyengar P, Scagliotti G, Ferrer L, Etchepare G, Gallinato O, Faure J, Bernard P, Colin T, Menu P, Lin[...]

Threading the Needle in Bladder Cancer: A Narrative Review of the Emerging Role of Integrative Oncology in Treatment-Related Adverse Events in the Era of Immunotherapy and Antibody-Drug Conjugates

Niknafs AM, Damron LF, Baclig NV, Iliopoulos M, Drakaki A. Threading the Needle in Bladder Cancer: A Narrative Review of the Emerging Role of Integrative[...]